Streetbeat News

Analyst Ratings

ENVX

EF Hutton analyst Tim Moore has reiterated a Buy rating on Enovix (NASDAQ:ENVX) and maintained a $24 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 4:20 pm

LIFE

HC Wainwright & Co. analyst Joseph Pantginis reiterated a Buy rating on aTyr Pharma (NASDAQ:LIFE) and maintained a $35 price target. This reaffirms the firm's positive outlook on the company.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 4:16 pm

KAR

Barrington Research analyst Gary Prestopino has reiterated an Outperform rating on Openlane (NYSE:KAR) and maintained a $25 price target.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 4:13 pm

WING

Stephens & Co. analyst Joshua Long has reiterated an Overweight rating on Wingstop (NASDAQ:WING) and maintained a $330 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 4:12 pm

HCKT

Barrington Research analyst Vincent Colicchio has reiterated an Outperform rating on The Hackett Group (NASDAQ:HCKT), maintaining a price target of $28.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 4:09 pm

RAPT

RAPT Therapeutics shares have declined following downgrades from multiple firms.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 4:04 pm

NEO

NeoGenomics Inc (NASDAQ:NEO) reported a Q4 2023 adjusted EPS of $0.03, surpassing consensus estimates and marking a turnaround from a previous loss. Sales rose 12.1% Y/Y to $155.55 million, also beating estimates. The company saw a 20% increase in Clinical Services revenue and a 17% decrease in Advanced Diagnostics revenue. Adjusted gross profit margin improved to 46.7%. Despite a net loss decrease to $14 million, adjusted EBITDA was positive at $9 million. For FY 2024, NeoGenomics forecasts an adjusted EPS of $0.04, against a consensus loss of $(0.08). William Blair maintains an Outperform rating, viewing legal issues as a temporary concern.

Portfolio Pulse from Vandana Singh

February 21, 2024 | 4:01 pm

IDYA

IDEAYA Biosciences (NASDAQ:IDYA) has seen varied analyst opinions over the past quarter, with recent updates showing a shift towards more bullish stances. The average 12-month price target has increased to $46.5, up from $37.20, indicating a positive outlook on the company's future. Analysts from firms like RBC Capital and Goldman Sachs have raised their price targets, reflecting optimism about IDEAYA's market position and its oncology-focused precision medicine developments. Despite a significant revenue decline of -72.94% as of September 30, 2023, the company's strong net margin and ROE suggest effective cost control and equity capital utilization.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 4:01 pm

UBER

The article provides an in-depth industry comparison of Uber Technologies (NYSE:UBER) against its competitors in the Ground Transportation industry, focusing on financial metrics, market position, and growth prospects. It highlights Uber's premium valuation with high PE, PB, and PS ratios compared to industry averages, but also points out its strong operational performance with higher ROE, EBITDA, gross profit, and revenue growth. The analysis suggests a mixed picture for Uber, indicating potential overvaluation but also strong growth prospects.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 4:00 pm

CCI

Analysts have recently updated their evaluations of Crown Castle (NYSE:CCI), with a consensus indicating a neutral stance but raising their 12-month price targets to an average of $111.0, up from $96.33. This adjustment reflects a more optimistic view of the company's future performance. Crown Castle, a major player in the U.S. cell tower and fiber sectors, has shown solid financials, including a revenue growth rate of 0.42% and a net margin of 21.57%, despite a challenging competitive environment.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 4:00 pm